Share This Page
Suppliers and packagers for eryc
✉ Email this page to a colleague
eryc
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Dr Reddys Labs Sa | ERYC | erythromycin | CAPSULE, DELAYED REL PELLETS;ORAL | 050536 | NDA AUTHORIZED GENERIC | Dr. Reddy's Labratories Inc. | 75907-076-01 | 100 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE, PLASTIC (75907-076-01) | 2024-09-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for eryc
ERYC (erythromycin) suppliers: API, contract manufacturing, and finished-dose sources in the US and EU
ERYC is used as a shorthand label for erythromycin products. Supplier coverage depends on the exact salt (e.g., erythromycin base, erythromycin ethylsuccinate), dosage form (tablet, suspension, ER), and market (US vs EU). Without the specific ERYC product identity (strength, salt form, dosage form, and FDA/EMA identifier), a complete supplier map cannot be produced.
Which companies supply erythromycin (ERYC) API and finished dose products?
A defensible supplier list requires tying “ERYC” to a specific erythromycin marketed product and its commercial source(s) via the relevant drug master file references, Orange Book/NDC mapping, or EU marketing authorization holder.
What is the typical erythromycin supply chain layout?
- API manufacturers for erythromycin (often via intermediates and fermentation-based upstream production)
- Salt/formulation manufacturers (e.g., ethylsuccinate for improved oral bioavailability in suspension/tablet formats)
- Finished-dose contract manufacturers (CMOs) for tablets and suspensions
- Marketing authorization holders (MAHs) for EU products
- Wholesalers and authorized distributors for retail and hospital supply
What supplier types must be distinguished for ERYC?
- API supply (primary liability for drug substance quality)
- Finished-dose manufacturing (GMP product line)
- Packagers/labelers (sometimes the “supplier” on the label)
- Marketing authorization holder vs manufacturer of record (key for IP and litigation mapping)
What patents protect ERYC (erythromycin) in the US?
A patent landscape for “ERYC” requires the exact product identity. For erythromycin, many core active-ingredient patents are long expired, but formulation, dosing regimen, and manufacturing process patents can still affect specific salts, ER formulations, and pediatric suspensions.
How strong is the patent estate for erythromycin products?
- Typically weak at the API level due to historical filing timelines
- May have active protection for specific dosage forms depending on whether the product is reformulated or re-engineered
When does ERYC lose exclusivity and what generic entry risks exist?
For erythromycin, generic competition is common, but market entry risk depends on:
- whether the product is tied to a specific FDA-listed NDA with exclusivities
- whether any listed patents remain in force (Orange Book)
- whether products use proprietary manufacturing controls or pediatric formulation constraints
What is the Orange Book status of ERYC (erythromycin) and how many patents are listed?
To answer precisely, the analysis must match the correct:
- FDA application number (NDA/ANDA/BLA)
- NDC strength and dosage form
- Orange Book listed patents (drug substance, drug product, method-of-use)
Which ERYC suppliers are most relevant for US hospitals and distributors?
US hospital procurement typically tracks:
- authorized distributors
- contracted wholesalers
- group purchasing organization (GPO) supply availability Mapping that to “ERYC” requires the specific NDC.
Which EU companies supply erythromycin products comparable to ERYC?
EU supply is governed by:
- EMA/ national marketing authorizations
- MAH and local QP release logistics A supplier list requires the exact MA number or at least the specific product identity.
How does ERYC compare with other macrolide antibiotics in supply concentration?
Erythromycin supply is often more dispersed than newer macrolides due to:
- older manufacturing base
- multi-source generics Competition and availability differ by dosage form, especially suspensions.
What manufacturing/IP barriers could block certain ERYC suppliers?
Key barriers are product-specific:
- validated formulation specifications (especially for suspensions)
- stability and shelf-life controls
- pediatric compliance and labeling requirements
- any still-active formulation or process patents tied to the exact branded product
Key Takeaways
- “ERYC” as a label is not sufficient to generate a complete, citation-ready supplier list.
- A precise supplier map requires tying ERYC to a specific erythromycin salt and dosage form and then mapping that to FDA/NDC (US) or MAH/authorization (EU).
- Supplier identification is materially different for API, finished-dose manufacturing, and label/authorization holder roles.
FAQs
- Which NDC corresponds to ERYC (erythromycin) and who manufactures it?
- Who are the main erythromycin API suppliers globally (US vs China vs EU)?
- Do erythromycin suspensions have fewer supplier options than tablets due to stability?
- What FDA listings (Orange Book patents) affect generic competition for specific erythromycin salts?
- Which companies supply erythromycin ethylsuccinate versus erythromycin base in finished doses?
References
No sources were provided or identified for the specific “ERYC” product identity, and no compliant supplier list can be generated without product-to-identifier mapping.
More… ↓
